Compositions and Methods For Inducing Apoptosis In Tumor Cells

• US 20110015126A1
• Filed: 03/11/2010
• Published: 01/20/2011
• Est. Priority Date: 07/22/1998
• Status: Abandoned Application

• Current Assignee: University of Connecticut (State of Connecticut)
• Original Assignee: E-P Therapeutics Incorporated
• Inventors: Chen, Thomas T., Chen, Maria J.M.
• Application Number:
  US12/721,659
• Publication Number:
  US 20110015126A1
• Time in Patent Office: Days
• US Class Current: 514/8.5
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/65 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• CPC Class Codes: C12N 2501/105 Insulin-like growth factors [IGF]
• CPC Class Codes: C12N 5/0018 Culture media for cell or tissue culture media for specific animal cell type C12N5/06

Abstract

A method is described for using an E-domain peptide for the induction of apoptosis in a cancer cells. In particular, the invention relates to methods for using a-type E-domain peptide from trout IGF and/or a b-type E-domain peptide from human IGF for the induction of apoptosis in a broad spectrum of cancer cells. The peptide species can be a homologue of the E-domain of IGF-1 or a fusion protein comprising the E-domain of IGF-1. It can be administered to one or more cancer cells alone or in a pharmaceutically acceptable composition.

Claims

1. (canceled)

2. (canceled)

3. (canceled)

4. (canceled)

5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

9. (canceled)

10. (canceled)

11. (canceled)

12. A method for treating cancer in an animal tissue comprising, providing an animal in need thereof, and administering an effective amount of at least one of an E-domain insulin-like growth factor (IGF-1) peptide composition selected from the group consisting of an Ea-4 domain peptide having the amino acid sequence of SEQ ID NO:

2, an hEb domain having the amino acid sequence of SEQ ID NO;

1, and combinations thereof, and wherein the E-domain peptide induces apoptosis in a cancer cell.

13. The method of claim 12, wherein the E-domain peptide composition comprises the peptide and one or more pharmaceutically acceptable adjuvants.

14. The method of claim 12, wherein the cancer cell is in vitro.

15. The method of claim 12, wherein the cancer cell is in vivo.

16. The method of claim 12, wherein the E-domain peptide composition further comprises another biologically active agent.

17. The method of claim 12, wherein the protein comprises a homologue of the E-domain of IGF-1, or a fusion protein comprising the E-domain of IGF-1.

18. The method of claim 12, wherein the peptide comprises the Ea-4 domain peptide having the amino acid sequence of SEQ ID NO:

2.

19. The method of claim 12 wherein the peptide comprises the hEb domain peptide having the amino acid sequence of SEQ ID NO:

1.

20. The method of claim 12 wherein the peptide comprises the Ea-4 domain peptide having the amino acid sequence of SEQ ID NO:

2 and hEb domain having the amino acid sequence of SEQ ID NO;

1.

21. The method of claim 12 wherein the peptide is comprised within a fusion protein.

22. The method of claim 12 wherein the cancer cell is selected from the group consisting of a breast cancer cell, colon cancer cell, neuroblastoma cell, kidney cancer cell, ovarian cancer cell, prostate cancer cell, and combinations thereof.

23. The method of claim 12, wherein the animal tissue is a human tissue.